Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  19.00 4.3% 461.00 30,841 16:35:04
Bid Price Offer Price High Price Low Price Open Price
455.00 459.00 465.00 443.00 443.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.24 -22.87 -26.10 382
Last Trade Time Trade Type Trade Size Trade Price Currency
17:22:48 O 157 461.924 GBX

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
07/8/202004:44Silence Therapeutics (the old SR Pharma)49,637
08/8/201906:43Lets Short This Duffer Out Of Business704
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
05/10/201620:29port-
29/5/201310:32Silence Therapeutics - news and views1,412

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-06 16:23:08461.92157725.22O
2020-08-06 15:35:04461.0011,54753,231.67UT
2020-08-06 15:29:50455.00731.85AT
2020-08-06 15:23:46459.005072,327.13AT
2020-08-06 15:22:35458.00123563.34AT
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

DateSubject
06/8/2020
09:20
Silence Therapeutics Daily Update: Silence Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 442p.
Silence Therapeutics Plc has a 4 week average price of 395p and a 12 week average price of 395p.
The 1 year high share price is 610p while the 1 year low share price is currently 165p.
There are currently 82,796,259 shares in issue and the average daily traded volume is 37,877 shares. The market capitalisation of Silence Therapeutics Plc is £381,690,753.99.
21/7/2020
14:33
1gw: With ARWR back over $50/share and $5bn market cap, it has been a great RNAi hedge against SLN's lacklustre performance in recent months. Since the close on 24th March, the day before the Astrazeneca announcement, up to yesterday's close, relative share price performances (from Yahoo! Finance data) have been: SLN +11% (or +18% in $ terms) ARWR +79% DRNA +42% And if I take 25th March close, the end of the day in which the AZN deal was announced, SLN is actually down (in £ terms). Perhaps the SLN shareprice has been showing signs of a bit more strength very recently, but still looking rangebound. And clearly you can argue ARWR has largely been recovering from the huge sell-off between December and March. But it feels to me as though if SLN can manage the communication around the Nasdaq listing, [edit] SLN360 IND/CTA and SLN124 clinical start there is still huge potential for it to play catchup in shareprice terms. Not to mention the upside potential of other deal announcements and maybe even new CEO and/or "biotech investors". I would hope the August conference participation is aimed at exactly that - improving communications, especially with potential US investors ahead of the Nasdaq listing. No advice intended.
23/6/2020
08:09
spectre10: Let's not forget the other positive news announced as well. SLN360 Preparations to submit to the FDA an investigational new drug (IND) package for the prioritised and wholly-owned asset, SLN360, are on schedule for later this year. SLN124 SLN124, in late stage pre-clinical development, has received Rare Paediatric Disease Designation (RPDD) for beta-thalassaemia and Orphan Drug Designation for myelodysplastic syndrome (MDS) from the FDA. Patient recruitment will recommence under two new protocols, SLN124-002 and SLN124-003, with clinical trial applications (CTAs) to be filed in H2 2020 for both protocols. Strengthened team Eric Floyd has been appointed as SVP, Head of Global Regulatory Affairs, Dr. John Whittaker has joined the Scientific Advisory Board. Strong cash position As of 29 May 2020, the Company had cash, cash equivalents and short-term deposits of GBP52.0 million, reflecting the proceeds from the issuance of ordinary shares to AstraZeneca in March 2020 and a $20 million upfront payment from AstraZeneca received in May 2020. The Company is unconditionally entitled to receive a further $40.0 million from AstraZeneca no later than the first half of 2021. https://uk.advfn.com/stock-market/london/silence-therapeutics-SLN/share-news/Silence-Therapeutics-PLC-Business-Update/82707742
22/5/2020
07:56
vonmoger: Aquilla, If he gets it listed with a share price over 4.40... he gets call it gbp220k (50k x4.40)*. The rest are quarterly and or in 3 years. Generous or not is in the eye of the beholder, personally I would of preferred more front loaded to the actual listing. The incentive is likely enough to get it done. I don't know what evidence others would require to see that this is happening rather than just an open ended intention.... I think DHS had a lot more options than this (from memory), so they have likely left some in the cupboard for the new CEO. I would guess the new CEO will get 1m+ options tied to share price performance and deals... * Personally I expect a higher share price... But for arguments sake.
21/5/2020
16:54
aquilla: Iain's doing quite well out of these options. I'm not very keen on these generous option packages but at least most of the options bear some resemblance to the existing share price and the really generous ones with a strike price of 5p will give further incentive to a US listing and an share price not too out of line with the present share price "350,000 options will be granted with a strike price of GBP4.40 and will vest quarterly over three years. 150,000 options will be granted with a strike price of 5p, of which 100,000 will vest on the third anniversary of Iain's appointment to the board in April 2019, subject to Silence achieving a listing on a US stock exchange. The remaining 50,000 options at 5p will vest upon achievement of a listing on a US stock exchange and subsequent achievement of a share price of GBP4.40 over 30-days." https://uk.advfn.com/stock-market/london/silence-therapeutics-SLN/share-news/Silence-Therapeutics-PLC-Grant-of-Share-Options/82512181
27/3/2020
11:34
1gw: If you want further rationalisation, given a lot of investors were expecting a further deal to be announced, I wouldn't be surprised if some had decided to take some profits here now that it has been. SLN suggested in the call I think that there was unlikely to be another deal announced for some time, while it sounded like they were working to get some biotech investors on board - I guess there may be an announcement of further funding raised by some kind of individual "placing" at some point, ahead of any actual “IPO”. So those existing investors wanting to raise funds to meet obligations elsewhere, or to invest in what they believe are unduly beaten-up stocks, may have decided this is a good time to take money out. It has been striking how relatively stable the SLN share price has been during the recent market plunge, when even gold and treasuries were apparently being sold by investors needing or wanting to raise cash.
25/3/2020
17:44
aquilla: The 16.8% increase in the share price today might seem a tad disappointing in view of the game changing deal. However it often takes a while for share prices to fully reflect events. Interesting to see the share price movement after previous events. On the 18th July, 2019 SLN announced collaboration with MNK. The share price went on to double over the next few days from around 80p to 200p before consolidating for a couple of months. In the first half of October Quested lifted its stake in SLN from 3.76% to 11.33% and the share price took a couple of weeks to double to 400p before consolidating for the next couple of weeks. It then went on to 600p before subsiding back to 300p. On the 7th of January the agreement with Takeda was announced. The sp, after falling back after the initial climb, subsequently went from 300p to 400p over the next couple of weeks. Possible factors which might affect the share price in the coming days: Positive: 1)Brokers' notes 2)Institutional interest Negative: 1)Already in the price (if news had leaked) ? 2)Coronavirus and the general effect on the market.
07/3/2020
20:44
vonmoger: K, Mnk and sln share prices do not follow each other what so ever. Historically or even more so now, when mnk is entering final stages of negotiations... So I am guessing that my thoughts that this mnk "problem" is not a problem... Is correct. So I can expect milestone payments under the current deal and triggering of two additional complement deals? Do you think that is what the market is waking up to,? If not is that news all to come? Ie. A positive surprise? Or does this article mean nothing?
01/3/2020
13:17
vonmoger: K If one thought that an announcement of an in-clinc trial (whatever your definition is) or a new CEO was going to be a share price increasing event... Wouldn't one buy before that news? If one waits for "clarity" and wants to be long, isn't one just watching share price increasing news flow take affect whilst one is on the sidelines? If one thinks a first dosing announcement is share price positive do you wait till after to buy? If one thinks a new CEO is a share price positive do you wait till after? If one thinks a deal will be share price positive do you wait till after? Etc. I bought before the news. It's a simple strategy. Gla
12/1/2020
01:06
vonmoger: 1gw, 2 things stuck out for me last week. * Only raising non-dilutive capital. * Edison note had only needing gbp105m of capital to reach profitability by 2026. 105m in the context of the capital raised by all the other RNAi companies over the past year is.... Tiny. Their guess of capital requirements is going to be better than mine. It is clear to me that they are going to raise far more than 105m through deals in 2020. The capital requirements will be higher than 105m by 2026. This is because they will have more currently undisclosed targets. They will ipo late 2020/early 21 as a marketing point to fund the undisclosed targets after deals with the share price way higher, imho. One can look back at ARWR listing in Jan 18. They announced a listing, share price went up not down, day of the announcement, day shares were issued closed up again. Why? Because the shares are capturing a higher percentage of the future value of the deals and not the partner of the deals is my guess. That and it appears that the equity raisings through deals are done at a premium. The "hope" by shorters that a raise might lower the share price might just be hope if history here is a guide. In any case and as before cash through second half 2021 at present. Deals will be done before a listing and the share price will be a lot higher than here when they ipo in the US likely end of the year. History is there with ARWR and dicerna. The owners have seen it. If one chooses to look one can see it. This company has far to much cash with the upcoming deals for the size of it's market cap and in comparison to it's competitors. The Edison note was a snapshot in time with no forward looking allowance or allowances for what is clearly going to happen if one looks at the playbook laid down by dicerna and ARWR. I agree it's misunderstood, which is amazing as the playbook is so clear to see... And UK retail investors have been told that it's happening numerous times.
18/9/2019
19:25
1gw: Time for a bit of idle M&A speculation? In January 2017, when Ali parked the Silence tanks on Arrowhead's lawn ("potential corporate transaction" and "product licensing" mentioned in press release, among other things), he bought 9% of the company (ARWR) at an average of around $1.65/share. At the time Silence was around £1/share I think. Today ARWR is trading at around $28.85/share and Silence closed at £2.40. The xrate is about the same (Jan 2017 vs today) at £1=$1.25. So ARWR has gone up around 17.5 times, while SLN has done a bit better than doubled since the announcement of SLN's purchase of the ARWR position. In 2017, ARWR was so worried about the SLN move that it put in place a poison pill if I recall correctly. So, economic logic to one side for a minute, can you imagine the satisfaction in the ARWR C-suite if they could pick up SLN for a fraction of what they might have been looking at in terms of a corporate transaction back in 2017 (in terms of share exchange ratio), when they scrambled to put defences in place? But then look at the economic logic. At the recent R&D event we had SLN trumpeting it's LP(a) asset SLN360, which appears to be a potential competitor of the ARWR/Amgen AMG890 asset. So acquisition of SLN would remove the LP(a) competition threat, enabling ARWR to choose the best LP(a) asset - maybe even manage the transition from AMG890, which should be available first, to SLN360 which might be superior. Also it would remove the risk of any patent disputes with Silence, and ARWR would be in a position to take the best from each company's platforms. And perhaps best of all, ARWR might judge it would be positioned to capture a decent chunk of the upside from Silence asset success, if it thinks the SLN market value has the potential to follow ARWR's shareprice trajectory of the last couple of years as the SLN assets move into and through the clinic. You then look at the SLN shareholder base. Around 50% of the company (I estimate) held between Ali, Griffiths, Keith and Quested. So fairly easy to see who ARWR need to get onside if they want a deal to happen. It seems to me ARWR could quite easily justify a really juicy multiple of the current SLN share price to get SLN in an all-paper (or largely paper) transaction. Whether they could offer enough to convince Ali & co that it was an attractive alternative to going it alone, I don't know, but it seems to me it is a reasonable possibility. Post offered to try to provoke some reaction/discussion. Errors excepted, and no advice intended.
Silence Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200807 04:01:28